Email this article 
THE AUTHOR’S EXPERIENCE IN USING BEVACIZUMAB PLUS INTERFERON ALFA-2A IN PATIENTS WITH DISSEMINATED RENAL CELL CARCINOMA
- Authors: Popov A.M.1, Karyakin O.B.1, Gorban N.A.1
-
Affiliations:
- Medical Radiology Research Center, Russian Academy of Medical Sciences, Obninsk
- Issue: Vol 6, No 4 (2010)
- Pages: 32-35
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCER
- Published: 30.12.2010
- URL: https://oncourology.abvpress.ru/oncur/article/view/330
- DOI: https://doi.org/10.17650/1726-9776-2010-6-4-32-35
- ID: 330
Cite item
Full Text
Abstract
Target therapy is a main approach to treating metastatic renal cell carcinoma. Bevacizumab plus interferon alfa-2A is now standard first-line options for patients with previously untreated, good or intermediate prognosis (using the Memorial Sloan-Kettering Cancer Center criteria). We have presented our experience in using bevacisumab plus interferon alfa-2A in patients with metastatic renal cell carcinoma. Median progression-free survival and overall survival were 10 months and 22 months, respectively.
About the authors
A. M. Popov
Medical Radiology Research Center, Russian Academy of Medical Sciences, Obninsk
Author for correspondence.
Email: apopov@mrrc.obninsk.ru
Russian Federation
O. B. Karyakin
Medical Radiology Research Center, Russian Academy of Medical Sciences, Obninsk
Email: apopov@mrrc.obninsk.ru
Russian Federation
N. A. Gorban
Medical Radiology Research Center, Russian Academy of Medical Sciences, Obninsk
Email: apopov@mrrc.obninsk.ru
Russian Federation
References
Supplementary files
